NovoCure (NVCR) Change in Cash (2014 - 2026)

NovoCure (NVCR) has reported Change in Cash for 13 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.

• Quarterly Change in Cash fell 72.28% year-over-year to $6.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$48.5 million (down 197.46% YoY) and the FY2025 annual result came in at -$62.7 million, up 18.0% from the prior year.
• Change in Cash rose to $6.3 million in Q2 2026 per NVCR's latest filing, from -$6.1 million in the prior quarter.
• Over the last five years, Change in Cash for NVCR reached as high as $214.8 million in Q1 2024 and fell as low as -$288.9 million in Q2 2024.
• A 5-year average of -$5.9 million and a median of -$3.5 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2024 — Change in Cash jumped 2213.65% — and 2025, when it plunged 944.14%.
• Year by year, Change in Cash stood at -$128.2 million in 2022, then surged by 167.12% to $86.1 million in 2023, then tumbled by 126.85% to -$23.1 million in 2024, then tumbled by 944.14% to -$241.2 million in 2025, then surged by 102.61% to $6.3 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $6.3 million, -$6.1 million, and -$241.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.